Adam Laponis compensation by year
Twist Bioscience Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $330,708 | $490,000 |
| Bonus | $195,000 | $0 |
| Stock awards | $4,197,600 | $3,365,430 |
| Option awards | $0 | $0 |
| Non-equity incentive | $280,624 | $349,197 |
| Pension and deferred compensation | $0 | $0 |
| All other | $4,312 | $11,490 |
| Total | $5,008,244 | $4,216,117 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Twist Bioscience Corp DEF 14A filed January 6, 2026, accession 0001581280-26-000006, and prior-year filings.
How this page was built: the Twist Bioscience Corp filed document, accession 0001581280-26-000006. Every figure is read from that document and cited to the page and table it appears in. Filed January 6, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 46,878 | $1,319,147 | — |
| PSU | 37,444 | $1,053,674 | — |
| PSU | 37,000 | $1,041,180 | — |
| PSU | 21,732 | $611,538 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Twist Bioscience Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
13 Form 4 lines since the FY2025 proxy (filed January 6, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-09 | Sale | — | 2,462 | $156.30 | 98,114 |
| 2026-10-02 | Sale | — | 8,057 | $188.88 | 100,576 |
| 2026-08-21 | Sale | — | 1,965 | $139.07 | 108,633 |
| 2026-07-09 | Sale | — | 2,399 | $94.33 | 110,276 |
| 2026-05-29 | Sale | 10b5-1 | 4,000 | $70.00 | 112,675 |
| 2026-05-21 | Sale | — | 2,019 | $53.26 | 116,675 |
| 2026-04-17 | Sale | 10b5-1 | 4,000 | $60.00 | 118,694 |
| 2026-04-14 | Sale | 10b5-1 | 3,000 | $55.00 | 122,694 |
The 8 most recent of 13 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Twist Bioscience discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,040,124 | $4,025,539 | $32,400 | $5,098,064 |
| Involuntary termination without cause | $245,000 | — | $3,193 | $597,390 |
Per the Potential Payments Upon Termination or Change in Control table in Twist Bioscience Corp's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Twist Bioscience’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Emily Leproust | Chief Executive Officer and Chair of the Board | $13,781,570 |
| Patrick Finn | President and Chief Operating Officer | $8,022,942 |
| Adam Laponis · this page | Chief Financial Officer | $4,216,117 |
| Dennis Cho | Chief Legal Officer and Corporate Secretary | $3,621,076 |
| Paula Green | Senior Vice President of Human Resources | $3,348,859 |
The full Twist Bioscience compensation record
free company briefThis page is one person within Twist Bioscience's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Twist Bioscience proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Twist Bioscience's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Twist Bioscience's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.